In a groundbreaking development that could reshape our understanding of diabetic kidney disease (DKD), researchers have unveiled a surprising new role for keratin 18 (K18), a protein previously known mainly for its structural duties in epithelial cells. This study reveals that K18 acts as a lactyltransferase, a novel enzymatic function that directly influences cell death pathways. Specifically, K18’s lactyltransferase activity triggers necroptosis, a form of programmed cell death, through modulation of Fas transcription, thereby offering fresh insights into the pathological mechanisms of diabetic kidney complications.
Diabetic kidney disease remains a major health burden worldwide, accounting for a significant proportion of chronic kidney disease cases and often leading to end-stage renal failure. Understanding the molecular players involved in DKD progression is crucial for developing targeted therapies. The discovery of K18’s enzymatic role opens a whole new dimension in DKD research, moving beyond classical views that confined keratins to purely structural or mechanical functions within cells.
At the core of this discovery is the concept of protein lactylation, a recently identified post-translational modification involving the attachment of lactate groups to lysine residues. This modification has been gaining attention as a metabolic signaling marker and regulator of gene expression. By demonstrating that K18 serves as a lactyltransferase, the study links metabolic by-products such as lactate to cellular fate decisions, notably necroptosis, which is distinct from apoptosis and characterized by inflammatory responses.
Necroptosis is instrumental in various chronic inflammatory diseases, including DKD, where it exacerbates tissue damage and promotes fibrosis. The researchers elucidated that K18’s lactyltransferase activity specifically upregulates Fas, a death receptor that initiates necroptotic signaling cascades. By increasing Fas transcription, K18 thereby amplifies necroptosis in renal epithelial cells, revealing a direct molecular bridge between metabolic shifts in diabetic conditions and programmed cell death pathways.
The intricate experiments combined molecular biology, biochemistry, and advanced proteomics to firmly establish K18’s unexpected catalytic activity. Previously, K18 was understood primarily as an intermediate filament protein contributing to cellular integrity. However, this study highlights that K18 can dynamically interact with chromatin and transcriptional machinery, influencing gene expression programs in response to intracellular metabolic states.
This finding prompts a reevaluation of keratin biology, suggesting that intermediate filament proteins may have multifaceted roles including enzymatic activities that modulate epigenetic and transcriptional landscapes. The enzymatic transfer of lactate onto histones or transcription factors could represent a broader paradigm of epigenetic regulation responsive to metabolic changes within cells.
Importantly, the study links elevated lactate levels, a hallmark of diabetic metabolism, to the enhancement of K18 enzymatic function. In hyperglycemic conditions commonly observed in diabetes, increased glycolysis and lactate production create a biochemical environment conducive to these modifications. This provides a mechanistic explanation for how metabolic dysregulation directly stimulates the progression of tissue damage in DKD.
From a clinical perspective, this research identifies K18 and its lactyltransferase activity as a potential therapeutic target. Inhibitors aimed at blocking this enzymatic function of K18 could mitigate necroptosis-driven renal injury, potentially halting or slowing DKD progression. Furthermore, the study opens avenues for the development of biomarkers based on K18 lactylation status, offering a new tool for early diagnosis or monitoring of renal damage in diabetic patients.
The broad implications extend beyond kidney disease, as necroptosis and lactylation have been implicated in other chronic and inflammatory conditions. Future studies might explore K18’s lactyltransferase role in cancer, neurodegeneration, or cardiovascular diseases, where metabolic dysfunction coexists with inflammation and cell death.
Additionally, this work underscores the importance of metabolism in regulating non-metabolic proteins traditionally viewed as static structural elements. The dynamic interplay between cellular metabolism and protein function, exemplified by K18, illustrates a complex regulatory network that cells utilize to adapt, survive, or trigger programmed death under stress.
The intricate relationship between lactylation and transcriptional control revealed here also complements the growing understanding of epigenetic modifications as critical modulators of disease. This expands the repertoire of known post-translational modifications involved in cell fate decisions and highlights metabolism as a central axis in epigenetics and pathophysiology.
By dissecting the mechanistic pathway—lactate production leading to K18-mediated Fas transcription upregulation and necroptosis activation—this work provides a comprehensive molecular narrative. It intricately connects cellular bioenergetics, enzymatic regulation, transcriptional reprogramming, and programmed cell death in diabetic kidney disease pathogenesis.
As we look to the future, the discovery invites the scientific community to reassess protein functions through the lens of metabolic regulation, encouraging further exploration into how intrinsic cellular metabolism dictates structural protein behavior and disease outcomes. The convergence of metabolic and transcriptional control mechanisms represents a fertile ground for translational research and therapeutic innovation.
In summary, the newly identified enzymatic function of K18 as a lactyltransferase represents a paradigm shift in understanding diabetic kidney disease. By modulating Fas transcription and triggering necroptosis, K18 emerges as a critical mediator linking metabolic disturbance to cellular demise. This breakthrough not only augments the molecular landscape of DKD but also heralds new strategies for intervention against a disease that continues to challenge patients and clinicians globally.
Subject of Research: Keratin 18 (K18) enzymatic function and its role in necroptosis within diabetic kidney disease.
Article Title: Keratin 18 functions as a lactyltransferase to trigger necroptosis in diabetic kidney disease by modulating Fas transcription.
Article References:
Zhao, Q., Liu, X., Yang, Y. et al. Keratin 18 functions as a lactyltransferase to trigger necroptosis in diabetic kidney disease by modulating Fas transcription. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01737-9
Image Credits: AI Generated
DOI: 12 June 2026
Tags: diabetic kidney disease molecular mechanismsdiabetic kidney disease progressionFas transcription regulation in DKDkeratin 18 lactyltransferase activitykeratin proteins beyond structural roleslactylation post-translational modificationmetabolic signaling in kidney cellsnecroptosis in diabetic kidneysnovel enzymatic functions of keratin 18programmed necroptosis pathwaysprotein lactylation in cell deathtargeted therapies for diabetic nephropathy
